Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Boehringer Ingelheim and ExpressionEdits will collaborate on the optimization of the expression of gene therapies ExpressionEdits announced a collaboration and licensing agreement with Boehringer ...

Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. November 22 ...